By Dr. Jaisingh Rajput, MD  Sleep is essential for heart health, but millions of Americans unknowingly suffer from sleep ...

Spending too much time on screens late into the night? It could be interfering with your natural sleep cycle by reducing ...

Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Centessa Pharmaceuticals plc shifts focus to ORX750 for sleep disorders after discontinuing SerpinPC. Click here to find out ...

Among patients with obstructive sleep apnea using CPAP, pitolisant given at 20 mg and 40 mg reduces excessive daytime sleepiness.

Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

A massive new study suggests bedtime screen time could be seriously damaging your sleep. Researchers found that even one ...

Alkermes has begun a randomised Phase II trial to assess the efficacy and safety of ALKS 2680 in adults with idiopathic ...

Aerin Medical’s 3-year study confirms VivAer® provides lasting relief for nasal obstruction (NAO), improving airflow, sleep, ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

Given sleep’s profound impact on well-being, unexplained daytime fatigue and disrupted sleep patterns necessitate a ...